Abstract 4855
Background
IDH1 R132H mutant (IDH1R132H) glioma patients have better prognosis compared with IDH1 wild-type (IDH1wt) patients. However, the molecular mechanism is largely unknown. In this study, we investigated the biological behaviors of IDH1R132H and IDH1wt glioma cells, intends to explore whether the IDH1R132H protein could affect radiosensitivity. Additionally, we studied potential cross-talk between IDH1 and Wnt/β-catenin signaling in regulating radioresistance.
Methods
We established stable transfected U87MG and SY5Y cell lines with IDH1R132H or IDH1wt gene. The proliferation, migration and invasion ability were determined respectively by CCK-8, wound healing assay and Transwell assay. The radiosensitivity was detected by colony formation assay after 0, 2, 4, 6, 8, 10Gy radiation. Using Western blot, we assayed changes in β-catenin protein of glioma cells before and after 10 Gy radiation.
Results
The glioma cells were divided into three groups: blank control group, IDH1R132H group and IDH1wt group after stable transfection. CCK-8 assay showed that proliferation was significantly decreased in IDH1R132H group. Wound healing assay and Transwell migration assay both showed that migration capacity of IDH1R132H group was reduced than the other two groups. Transwell invasion assay also showed that IDH1R132H group has the lowest invasion rate. After 10Gy radiation, the proliferation, migration and invasion ability of IDH1R132H group was further lower than the other two groups. Similarly, colony formation assay showed formation rate of IDH1R132H group was reduced than the other groups. Western blot revealed that β-catenin protein was declined in IDH1R132H group. Furthermore, after 10Gy radiation, β-catenin protein increased in all three groups, but it was more obvious in IDH1wt group.
Conclusions
These data suggest that IDH1R132H mutation leads to a less aggressive biological behavior and increase the radiosensitivity. The molecular mechanism may be that IDH1 can activate the Wnt/β-catenin signaling pathway. Radiotherapy in combination with inhibitor of Wnt/β-catenin signaling may be an attractive approach for IDH1wt glioma patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Second Hospital of Hebei Medical University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4526 - Long-term outcome of neoadjuvant tyrosine kinase inhibitors (TKI) in locally advanced dermatofibrosarcoma protuberans (DFSP)
Presenter: Jessica Beaziz
Session: Poster Display session 1
Resources:
Abstract
1214 - Neo-adjuvant (NA) Imatinib for gastrointestinal stromal tumours (GISTs): What is the optimal length of treatment?
Presenter: Tom Wilson
Session: Poster Display session 1
Resources:
Abstract
2690 - Gastrointestinal Stromal Tumours (GIST) in adolescents and young adults (AYA)
Presenter: Nikki Ijzerman
Session: Poster Display session 1
Resources:
Abstract
4558 - Radiomics improves response evaluation for desmoid tumors treated with chemotherapy
Presenter: Amandine Crombe
Session: Poster Display session 1
Resources:
Abstract
2751 - Radiomics of gastrointestinal stromal tumors; risk classification based on computed tomography images – a pilot study
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract
2737 - Differentiating well-differentiated liposarcomas from lipomas using a radiomics approach
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
1282 - The immune landscape of chondrosarcoma reveals an anti inflammatory environment
Presenter: Iseulys Richert
Session: Poster Display session 1
Resources:
Abstract
1572 - Impact of Immunotherapy and Targeted Therapy on Tumor Growth Rate in Sarcoma
Presenter: Esmail Al-ezzi
Session: Poster Display session 1
Resources:
Abstract
3414 - DNA methylation profiles of angiosarcoma subtypes.
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
3411 - Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As and BTN3A1 in patients with metastatic gastrointestinal stromal tumors (mGISTs)
Presenter: Daniele Fanale
Session: Poster Display session 1
Resources:
Abstract